GLPwatch
Papers (12034)
Page 166 of 201, ranked by citation count.
- Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.
- [Pharmacotherapy of obesity in Germany].
- Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.
- Liraglutide: Weight loss injection is effective in children aged 6-11, study reports.
- Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
- Comparative Effectiveness of SGLT2 Inhibitors and Semaglutide in Diabetic Nephropathy: A Retrospective Observational Study.
- Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
- Management of diabetes and pancreatic cancer.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.
- Liraglutide as a treatment option for weight regain after laparoscopic sleeve gastrectomy in patients with obesity and higher anaesthesiologist risk.
- Ethical considerations for semaglutide use in children.
- Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).
- From weight loss to muscle loss: rhabdomyolysis linked to semaglutide.
- One small molecule for man, one giant leap for mankind with obesity.
- GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology.
- Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway.
- Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study.
- A Systemic Review of Pharmacological Management of Pediatric Obesity.
- Microbial expression of Exendin-4 analog and its efficacy in mice model.
- HYPOTHYROIDISM COULD BE A POTENTIAL FACTOR TO PROLONG SUBCUTANEOUS NODULES OF EXENATIDE ONCE WEEKLY: A CASE REPORT.
- ADDITION OF DULAGLUTIDE FOR A HIGH-DOSE INSULIN REQUIRING PATIENT WITH TYPE 2 DIABETES MELLITUS: A REMARKABLE RESPONSE.
- [For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?]
- Treatment of obesity in spinal cord injury with tirzepatide: a case report.
- Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
- [Treatment of non-alcoholic fatty liver disease].
- Euglycemic Diabetic Ketoacidosis in the Setting of Dulaglutide Use.
- Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy.
- Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data".
- Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.
- Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex-sumo wrestler.
- GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus.
- Choosing injectable therapy: The metabolic fulcrum.
- Gateways to clinical trials.
- Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention.
- 15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist-Induced Weight Loss.
- Dulaglutide-Associated Choroidal Lymphoid Hyperplasia.
- Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome.
- A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use.
- Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.
- Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.
- The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.
- Influence of pH, Buffering Capacity, Ionic Strength, Bile Salts, and Model Drugs on Micellization Behaviour of Salcaprozate Sodium in Physiological Range pH Buffers.
- [Glycemia normalization in patients with obesity and type 2 diabetes mellitus: bariatric surgery vs pharmacological therapy].
- Exploratory safety investigations in normal, freely moving Göttingen Minipigs using telemetry: Pharmacological validation.
- Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.
- Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.
- Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
- Slimming cardiac adipose tissue with liraglutide: pericardial is not epicardial fat (the LIRAFLAME substudy).
- Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large.
- Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.
- In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
- Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target.
- Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
- Exenatide substantially improves proinsulin conversion and cell survival that augment Ins2<sup>+/Akita</sup> beta cell function.
- Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL.
- Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.
- A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.
- Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient.
- When New Therapies Meet Old Challenges: Tirzepatide-Warfarin Interaction in A Mechanical Mitral Valve Patient.
- Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.